Table 2 Pathologic and adjuvant therapy outcomes after inverse probability of treatment weighting
Variable | Surgical approach | P Value | |
|---|---|---|---|
TaTME, No. (%) | LapTME, No. (%) | ||
Total, No. | 344 | 366 | |
AJCC pathological stage | |||
0 | 38 (11.0) | 32 (8.7) | 0.8616 |
I | 90 (26.1) | 92 (25.1) | |
II | 123 (35.7) | 119 (32.5) | |
III | 93 (27.0) | 123 (33.6) | |
IV | 0 (0.0) | 0 (0.0) | |
Mesorectal specimen | |||
Complete | 318 (93.2) | 242 (89.3) | 0.1678 |
Near-complete | 20 (5.8) | 13 (4.8) | |
Incomplete | 3 (0.8) | 16 (5.9) | |
Distance to CRM, mm (median, 95% CI) | 10.0 (10.0–12.0) | 7.5 (6.0–10.0) | 0.0131 |
CRM involvement | 32 (9.5) | 56 (16.2) | 0.0038 |
Distance to DRM, mm (median, 95% CI) | 20.0 (20.0–25.0) | 19.5 (15.0–20.0) | 0.248 |
DRM involvement | 6 (1.8) | 7 (2.0) | 0.6135 |
Rectal perforation | 2 (0.8) | 8 (3.2) | 0.0262 |
Composite poor pathological outcomea | 35 (10.6) | 69 (24.7) | < 0.001 |
Perineural invasion | 44 (13.0) | 47 (18.3) | 0.0109 |
Lymphovascular invasion | 68 (21.4) | 44 (17.0) | 0.0182 |
Budding | |||
no | 155 (82.8) | 38 (52.7) | 0.0002 |
low | 23 (12.3) | 32 (44.4) | |
moderate | 2 (1.0) | 0 (0.0) | |
high | 7 (3.7) | 2 (2.7) | |
Differential grade | 0.5589 | ||
good | 20 (6.3) | 15 (4.8) | 0.5589 |
moderate | 254 (80.3) | 240 (77.4) | |
poor | 17 (5.3) | 22 (7.1) | |
Number of lymph node harvested (median, 95% CI) | 15.0 (15.0–16.0) | 14.0 (14.0–15.0) | 0.0133 |
Adjuvant chemotherapy | 42 (12.2) | 61 (17.1) | 0.0508 |
Adjuvant radiotherapy | 4 (1.1) | 15 (4.2) | 0.0002 |